2024
Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease
Krishnamurti L, Liang J, He Z, Deng Y, Nallagatla V, Hamidi R, Flagg A, Shah N. Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease. Blood Advances 2024, 8: 1908-1919. PMID: 38324722, PMCID: PMC11021890, DOI: 10.1182/bloodadvances.2023010749.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseVaso-occlusive episodesPainful crisesCell transplantationPost-HCTGraft failureBefore HCTEvent-free survivalOverall survivalPain syndromePatient agePatient-centered outcomesAlternative donorsIncreased riskCell diseaseRisk factorsNatural historyPatientsLogistic regressionPainTransplantationSurvivalAgeAGVHDRisk Factors for the Development of Non-Infectious Pulmonary Complications Post-Hematopoietic Cell Transplantation in Sickle Cell Disease
Nallagatla V, Deng Y, Liang J, Krishnamurti L. Risk Factors for the Development of Non-Infectious Pulmonary Complications Post-Hematopoietic Cell Transplantation in Sickle Cell Disease. Transplantation And Cellular Therapy 2024, 30: s67. DOI: 10.1016/j.jtct.2023.12.106.Peer-Reviewed Original ResearchNon-infectious pulmonary complicationsAcute respiratory distress syndromeIdiopathic pneumonia syndromeMatched unrelated donorsPost-HCTPulmonary complicationsMechanical ventilationHLA mismatchesRisk factorsUnrelated donorCenter for International Blood and Marrow Transplant Research (CIBMTR) registryIncreased riskAssociated with pulmonary complicationsTransplant-related risk factorsPost-hematopoietic cell transplantationComplications of HCTPost-HCT complicationsHistory of ACYear of transplantationRespiratory distress syndromeTransplant-related factorsMultivariate logistic regression modelMultivariate logistic regressionDisease-related factorsPneumonia syndrome
2023
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease
Eapen M, Brazauskas R, Williams D, Walters M, St Martin A, Jacobs B, Antin J, Bona K, Chaudhury S, Coleman-Cowger V, DiFronzo N, Esrick E, Field J, Fitzhugh C, Kanter J, Kapoor N, Kohn D, Krishnamurti L, London W, Pulsipher M, Talib S, Thompson A, Waller E, Wun T, Horowitz M. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. Journal Of Clinical Oncology 2023, 41: 2227-2237. PMID: 36623245, PMCID: PMC10448940, DOI: 10.1200/jco.22.01203.Peer-Reviewed Original ResearchConceptsLow-intensity regimensSickle cell diseaseSecondary neoplasmsRisk factorsCell diseaseLeukemia/myelodysplastic syndromeMixed donor chimerismReduced-intensity regimensFull donor chimerismHematopoietic cell transplantTotal body irradiationLow-dose radiationGray regression modelsMyeloid mutationsPrior inflammationCell transplantMyelodysplastic syndromeTolerance inductionIntense regimensPlausible etiologyHigh riskRegimensSolid tumorsNeoplasmsMyeloid malignancies
2022
21 Sickle Cell Disease Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Children Undergoing Hematopoietic Cellular Therapy
Schoettler M, Spencer K, Lutterman D, Rumbika S, Haight A, Stenger E, Parikh S, Qayed M, Watkins B, Krishnamurti L, Williams K, Chonat S. 21 Sickle Cell Disease Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Children Undergoing Hematopoietic Cellular Therapy. Transplantation And Cellular Therapy 2022, 28: s20-s21. DOI: 10.1016/s2666-6367(22)00182-8.Peer-Reviewed Original Research58 Prevalence of and Risk Factors for Cardiac, Pulmonary, and Neurologic Dysfunction Following Hematopoietic Cell Transplant for Sickle Cell Disease: A STAR Study
Stenger E, Chellapandian D, Shah R, Gillepsie S, Xiang Y, Bhatia M, Chaudhury S, Eckrich M, Guilcher G, Jaroscak J, Kasow K, Krajewski J, Ngwube A, Olson T, Rangarajan H, Horan J, Krishnamurti L, Shenoy S, Abraham A. 58 Prevalence of and Risk Factors for Cardiac, Pulmonary, and Neurologic Dysfunction Following Hematopoietic Cell Transplant for Sickle Cell Disease: A STAR Study. Transplantation And Cellular Therapy 2022, 28: s49-s51. DOI: 10.1016/s2666-6367(22)00219-6.Peer-Reviewed Original Research
2021
A Decision Support Tool for Allogeneic Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: Acceptability and Usability Study
Veludhandi A, Ross D, Sinha C, McCracken C, Bakshi N, Krishnamurti L. A Decision Support Tool for Allogeneic Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: Acceptability and Usability Study. JMIR Formative Research 2021, 5: e30093. PMID: 34709190, PMCID: PMC8587189, DOI: 10.2196/30093.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationSickle cell diseaseAllogeneic hematopoietic stem cell transplantationHealth care providersStem cell transplantationCare providersCell transplantationPatient consultsCell diseaseHCT comorbidity indexPhysician-patient collaborationOttawa Decision Support FrameworkChronic blood transfusionsDisease-modifying therapiesTransplant registry dataMost participantsHealth care settingsQuality of lifePatient-specific measuresCurative intentComorbidity indexHCT outcomesBlood transfusionRisk factorsPatient management
2020
Risk Factors and Cardiovascular Disease (CVD) Related Outcomes in Hospitalized Patients with Hemophilia 10 Year Follow up
Day J, Gupta A, Abro C, Jung K, Krishnamurti L, Takemoto C, Goel R. Risk Factors and Cardiovascular Disease (CVD) Related Outcomes in Hospitalized Patients with Hemophilia 10 Year Follow up. Blood 2020, 136: 30-31. DOI: 10.1182/blood-2020-136486.Peer-Reviewed Original ResearchCVD risk factorsAcute myocardial infarctionAtherosclerotic coronary artery diseaseCVD outcomesCoronary artery diseaseNationwide Inpatient SamplePrevalent risk factorsRisk factorsCardiovascular diseaseHaemophilia populationOrder of frequencyHemophilia AArtery diseaseHeart failureHospitalized patientsHaemophilia patientsMean agePrevalence ratesJohns Hopkins Institutional Review BoardUtilization Project Nationwide Inpatient SampleUnadjusted prevalence ratesCardiovascular risk factorsSignificant riskCrude prevalence rateICD-9 codes
2019
Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)
Stenger E, Phelan R, Shaw B, Battiwalla M, Bo-Subait S, Brazauskas R, Buchbinder D, Hamilton B, Shenoy S, Krishnamurti L. Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood 2019, 134: 697. DOI: 10.1182/blood-2019-128797.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseAcute chest syndromeMarrow Transplant ResearchLate effectsCumulative incidenceRisk factorsChest syndromeInternational BloodAvascular necrosisMultivariable analysisUnrelated donorsPatient populationTransplant ResearchCell diseaseAllogeneic hematopoietic cell transplantMyeloablative hematopoietic cell transplantationVaso-occlusive pain crisesAllogeneic hematopoietic cell transplantationDiagnosis of SCDMultivariable Cox regression analysisFirst hematopoietic cell transplantationOlder ageExcellent overall survivalHematopoietic cell transplant
2017
Acute Chest Syndrome in Children with Sickle Cell Disease
Jain S, Bakshi N, Krishnamurti L. Acute Chest Syndrome in Children with Sickle Cell Disease. Pediatric Allergy Immunology And Pulmonology 2017, 30: 191-201. PMID: 29279787, PMCID: PMC5733742, DOI: 10.1089/ped.2017.0814.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute chest syndromeSickle cell diseaseHistory of asthmaVaso-occlusive crisisChest syndromeLung diseaseRisk factorsCell diseaseIncidence of ACSAcute vaso-occlusive crisisSteady-state hemoglobin levelsWhite blood cell countNew pulmonary infiltratesNew respiratory symptomsSevere SCD genotypesMild respiratory illnessPresence of feverChronic lung diseaseFetal hemoglobin concentrationPulmonary fat embolismRespiratory distress syndromeTobacco smoke exposureAcute lung diseaseBlood cell countChest X-ray
2016
CMV Viremia and African-American Ethnicity Are Risk Factors for Post-Engraftment Blood Stream Infections in Pediatric Allogeneic Blood and Marrow Transplantation
Sano H, Hilinski J, Applegate K, Camacho-Gonzalez A, Chandrakasan S, Chiang K, Haight A, Krishnamurti L, Stenger E, Qayed M, Horan J. CMV Viremia and African-American Ethnicity Are Risk Factors for Post-Engraftment Blood Stream Infections in Pediatric Allogeneic Blood and Marrow Transplantation. Blood 2016, 128: 3397. DOI: 10.1182/blood.v128.22.3397.3397.Peer-Reviewed Original ResearchBlood stream infectionsAfrican American ethnicityCMV viremiaAllogeneic BMTAllogeneic bloodMarrow transplantationRisk factorsMultivariate analysisGrade III/IVAllogeneic BMT patientsAlternative donor transplantsFrequency of neutropeniaPost-engraftment periodPre-emptive therapyTransplant related mortalityGram-positive cocciAcute GVHDBMT patientsCytomegalovirus viremiaEngrafted patientsUnrelated cordsUnrelated marrowClinical characteristicsCMV infectionCumulative incidence
2014
Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom
Gladwin M, Barst R, Gibbs J, Hildesheim M, Sachdev V, Nouraie M, Hassell K, Little J, Schraufnagel D, Krishnamurti L, Novelli E, Girgis R, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Castro O, Taylor J, Goldsmith J, Kato G, Gordeuk V, Machado R, Investigators and Patients O. Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. PLOS ONE 2014, 9: e99489. PMID: 24988120, PMCID: PMC4079316, DOI: 10.1371/journal.pone.0099489.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemia, Sickle CellBlood Flow VelocityBlood PressureCohort StudiesCreatinineFemaleFerritinsFollow-Up StudiesHemolysisHumansHypertension, PulmonaryKaplan-Meier EstimateMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsProportional Hazards ModelsRisk FactorsSeverity of Illness IndexUnited KingdomUnited StatesWalkingConceptsTricuspid regurgitation velocitySickle cell diseaseNT-proBNPCell diseaseMean pulmonary artery pressurePg/Pulmonary artery systolic pressurePulmonary artery pressureRisk of deathCause of mortalityPositive predictive valuePg/mLArtery pressurePulmonary hypertensionChronic transfusionScreening cohortHemolytic markersSystolic pressureCumulative survivalMale genderRisk factorsHigh riskPredictive valueClass IIIPatients
2012
Risk Factors for Death in 632 Patients with Sickle Cell Anemia in the United States and United Kingdom
Gladwin M, Barst R, Gibbs J, Hildesheim M, Sachdev V, Nouraie M, Hassell K, Little J, Schraufnagel D, Krishnamurti L, Novelli E, Girgis R, Zhang Y, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Castro O, Taylor J, Goldsmith J, Gordeuk V, Kato G, Machado R. Risk Factors for Death in 632 Patients with Sickle Cell Anemia in the United States and United Kingdom. Blood 2012, 120: 3240. DOI: 10.1182/blood.v120.21.3240.3240.Peer-Reviewed Original ResearchTricuspid regurgitant jet velocityHigher tricuspid regurgitant jet velocityProportional hazards regression analysisHigher NT-proBNPUnadjusted hazard ratioNT-proBNPHazards regression analysisSickle cell diseasePulmonary hypertensionRisk factorsGlaxo Smith KlineAspartate aminotransferaseHazard ratioCell diseaseCox proportional hazards regression analysisMean pulmonary artery pressureSix-minute walk distanceSickle cell disease patientsPopulation screening studiesPulmonary artery pressureRight heart catheterizationRegurgitant jet velocityRisk of deathDoppler echocardiographic measurementsScreening study
2008
Hematopoietic stem cell transplantation for hemoglobinopathies: Progress and prospects
Krishnamurti L, Gupta D. Hematopoietic stem cell transplantation for hemoglobinopathies: Progress and prospects. Indian Journal Of Medical And Paediatric Oncology 2008, 29: 39-48. DOI: 10.4103/0971-5851.51444.Peer-Reviewed Original ResearchSickle cell diseaseRisk factorsAllogeneic bone marrow transplantationClass IIHematopoietic stem cell transplantationClass ITransplant related morbidityUnrelated donor transplantsHLA-identical donorHLA-identical siblingsStem cell transplantationBone marrow transplantationCourse of diseaseLong-term survivalYears of ageAntithymocyte globulinAllogeneic SCTTransplant outcomesDonor transplantsRelated morbidityMarrow transplantationCell transplantationCell diseaseProbability of survivalTerm survival